20 stories mentioning INCY
Every FINWIRES story that references INCY, newest first.
Incyte (INCY) has an average rating of overweight and mean price target of $110.82, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Incyte (INCY) has an average rating of overweight and mean price target of $109.57, according to analysts polled by FactSet.Price: $103.10, Change: $+2.46, Percent Change: +2.44%
Thomas Tray, Principal Accounting Officer, on June 04, 2026, sold 2,639 shares in Incyte (INCY) for $263,900. Following the Form 4 filing with the SEC, Tray has control over a total of 21,132 common shares of the company, with 21,132 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/879169/000191231726000009/xslF345X05/wk-form4_1780949070.xml
Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index shedding 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.1%.The iShares Biotechnology ETF (IBB) fell 0.9%.In corporate news, Johnson & Johnson (JNJ) eased 0.3% after the firm said it has agreed to buy cancer drug developer Firefly Bio for $1 billion in cash to strengthen its oncology portfolio.Incyte (INCY) agreed to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, in a deal worth up to $2 billion, expanding its hematology portfolio into bleeding disorders. Shares fell 1%.Eli Lilly (LLY) shares rose 1.6% after the drugmaker said its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and also showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea.Tango Therapeutics (TNGX) surged 51% after the firm said initial results from its phase 1/2 trial of vopimetostat plus Revolution Medicines' daraxonrasib showed a six-month progression-free survival rate of 90% in people with pancreatic cancer.
Incyte (INCY) has an average rating of overweight and mean price target of $109.57, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $101.13, Change: $-1.26, Percent Change: -1.23%
Healthcare stocks were lower Monday afternoon, with the NYSE Healthcare Index shedding 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.3%.The iShares Biotechnology ETF (IBB) fell 1%.In corporate news, Johnson & Johnson (JNJ) decreased 0.8% after the company said Monday that it has agreed to acquire cancer drug developer Firefly Bio for $1 billion in cash to strengthen its oncology portfolio.Incyte (INCY) agreed to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, in a deal worth up to $2 billion, expanding its hematology portfolio into bleeding disorders. Shares fell 3%.Eli Lilly (LLY) shares rose 2.2% after the drugmaker said its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and also showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea.
Incyte (INCY) agreed to acquire Star Therapeutics unit Vega Therapeutics in a deal worth up to $2 billion, expanding its hematology portfolio into bleeding disorders.Star Therapeutics will receive $1.25 billion upfront, with up to $750 million in milestones payments, biopharmaceutical company Incyte said Monday.Vega Therapeutics' lead candidate, VGA039, improves hemostasis that helps control blood loss in bleeding disorders, Incyte said. The investigational drug is currently in a late-stage trial for patients with von Willebrand disease, the most common inherited bleeding disorder."VGA039 fits directly into our strategy of building a top-tier growth company for the future," Incyte Chief Executive Bill Meury said in a statement. "It is a first-in-class, phase 3 asset with compelling early data, a manageable development path and the potential to become an important new growth driver in one of our core therapeutic areas -- hematology."The transaction is expected to close in the third quarter."VGA039 will be advanced by Incyte," Star Therapeutics CEO Adam Rosenthal said.Incyte expects the Hart-Scott-Rodino review to result in a research-and-development charge of about $1.25 billion in third-quarter and full-year results.Price: $103.24, Change: $+0.86, Percent Change: +0.84%
Incyte (INCY) has an average rating of overweight and mean price target of $109.57, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Paul J Clancy, Director, on May 19, 2026, sold 15,000 shares in Incyte (INCY) for $1,423,950. Following the Form 4 filing with the SEC, Clancy has control over a total of 23,741 common shares of the company, with 23,741 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/879169/000140960126000006/xslF345X05/wk-form4_1779393732.xml
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 earnings, we keep our target at $102, 11.8x our projected 2027 EPS forecast, below its five-year historical forward P/E average of 17.0x. We adjust our 2026 EPS estimate to $7.83 from $7.94 and our 2027 EPS view to $8.64 from $8.36. INCY reported a solid start to 2026, beating expectations on both revenue and earnings, led by robust, double-digit growth across its commercial portfolio. We think the company is going through a strategic transition beyond its cornerstone product, Jakafi, toward a diversified portfolio in hematology, oncology, and immunology, supported by a maturing late-stage pipeline and key management appointments. INCY announced the appointments of Suketu Upadhyay (the current CFO of ZBH) as its new CFO, effective May 4, and a new Head of U.S. Commercial, Mohamed Issa. While we see some execution risks ahead, we believe INCY could be at an inflection point with four new product launches in the next year and the advancement of the 10 Phase 3 studies while filling key leadership roles.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 earnings, we keep our target at $102, 11.8x our projected 2027 EPS forecast, below its five-year historical forward P/E average of 17.0x. We adjust our 2026 EPS estimate to $7.83 from $7.94 and our 2027 EPS view to $8.64 from $8.36. INCY reported a solid start to 2026, beating expectations on both revenue and earnings, led by robust, double-digit growth across its commercial portfolio. We think the company is going through a strategic transition beyond its cornerstone product, Jakafi, toward a diversified portfolio in hematology, oncology, and immunology, supported by a maturing late-stage pipeline and key management appointments. INCY announced the appointments of Suketu Upadhyay (the current CFO of ZBH) as its new CFO, effective May 4, and a new Head of U.S. Commercial, Mohamed Issa. While we see some execution risks ahead, we believe INCY could be at an inflection point with four new product launches in the next year and the advancement of the 10 Phase 3 studies while filling key leadership roles.
Incyte (INCY) has an average rating of overweight and mean price target of $109.86, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $98.04, Change: $+0.30, Percent Change: +0.31%
Incyte (INCY) has an average rating of overweight and mean price target of $109.86, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $97.78, Change: $+0.04, Percent Change: +0.04%
Incyte (INCY) has an average rating of overweight and mean price target of $109.86, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $97.78, Change: $+0.04, Percent Change: +0.04%
Incyte (INCY) has an average rating of overweight and mean price target of $109.86, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $97.78, Change: $+0.04, Percent Change: +0.04%
Incyte (INCY) has an average rating of overweight and mean price target of $109.86, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $101.14, Change: $+3.40, Percent Change: +3.47%
Incyte (INCY) has an average rating of overweight and mean price target of $109.10, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $94.83, Change: $-0.89, Percent Change: -0.93%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Incyte delivered robust Q1 2026 results with total revenue of $1.27B (+21% Y/Y) and net sales of $1.10B (+20% Y/Y), significantly above expectations. Strong performance was driven by effective commercial execution across the diversified portfolio, with Jakafi maintaining momentum at $758M (+7% Y/Y) and Opzelura continuing impressive growth at $143M (+20% Y/Y). We view the exceptional hematology and oncology portfolio growth of $204M (+116% Y/Y), led by Niktimvo, Monjuvi, and Zynyz, as a critical strategic diversification beyond Jakafi ahead of the 2029 patent cliff. The company reaffirmed full-year 2026 guidance across all categories, expecting total net sales of $4.77B-$4.94B. We believe Incyte's advanced pipeline, with 10 Phase 3 studies including positive povorcitinib results in vitiligo and the pivotal DAWN-303 KRASG12D inhibitor trial, positions the company well for long-term growth under CEO Bill Meury's strategic focus on high-potential assets.
Damora Therapeutics (DMRA) is capitalizing on growing validation of using mutant calreticulin targeting therapies in myeloproliferative neoplasms, and may have the additional advantage of acharted regulatory path as a fast-follower over Incyte's (INCY) mid-stage candidate, RBC Capital said in a note emailed Friday.RBC said data from Incyte's (INCY) CALR antibody program have helped reduce uncertainty around the mechanism, strengthening confidence in its potential for treating conditions such as essential thrombocythemia and myelofibrosis.Damora's lead candidate DMR-001 may offer advantages such as extended half-life via YTE technology, higher potency, and a more consistent activity profile across mutation types, potentially addressing limitations of competing therapies, according to the report.The analyst sees DMR-001 reaching about $1.7 billion in peak U.S. potential, supported by improved dosing convenience and broader applicability, with a 60% probability of success in essential thrombocythemia and 35% in myelofibrosis.The firm said it expects the company's shares to appreciate to levels reflecting its long-term top-line potential.The report added that competitive clinical readouts could help de-risk the program, with early mid-2027 data viewed as a key potential catalyst for upside.RBC initiated the coverage on the company with an outperform rating on the stock with a price target of $40.Price: $24.02, Change: $-1.40, Percent Change: -5.51%
Pablo J Cagnoni, President, Global Head of R&D, on April 17, 2026, sold 18,667 shares in Incyte (INCY) for $1,801,366. Following the Form 4 filing with the SEC, Cagnoni has control over a total of 262,692 common shares of the company, with 262,692 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/879169/000120570326000012/xslF345X05/wk-form4_1776802145.xml